BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 35681696)

  • 1. Personalised Risk Prediction in Hereditary Breast and Ovarian Cancer: A Protocol for a Multi-Centre Randomised Controlled Trial.
    Archer S; Fennell N; Colvin E; Laquindanum R; Mills M; Dennis R; Stutzin Donoso F; Gold R; Fan A; Downes K; Ford J; Antoniou AC; Kurian AW; Evans DG; Tischkowitz M
    Cancers (Basel); 2022 May; 14(11):. PubMed ID: 35681696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS
    Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of two evidence-based decision aids for female BRCA1/2 mutation carriers in Germany: study protocol for a randomised controlled parallel-group trial.
    Kautz-Freimuth S; Redaèlli M; Isselhard A; Shukri A; Vodermaier A; Rhiem K; Schmutzler R; Stock S
    Trials; 2022 Feb; 23(1):157. PubMed ID: 35172875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancing the BOADICEA cancer risk prediction model to incorporate new data on
    Lee A; Mavaddat N; Cunningham A; Carver T; Ficorella L; Archer S; Walter FM; Tischkowitz M; Roberts J; Usher-Smith J; Simard J; Schmidt MK; Devilee P; Zadnik V; Jürgens H; Mouret-Fourme E; De Pauw A; Rookus M; Mooij TM; Pharoah PP; Easton DF; Antoniou AC
    J Med Genet; 2022 Dec; 59(12):1206-1218. PubMed ID: 36162851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of the BOADICEA model in a prospective cohort of
    Yang X; Mooij TM; Leslie G; Ficorella L; Andrieu N; Kast K; Singer CF; Jakubowska A; van Gils CH; Tan YY; Engel C; Adank MA; van Asperen CJ; Ausems MGEM; Berthet P; ; Collee MJ; Cook JA; Eason J; Spaendonck-Zwarts KYV; Evans DG; Gómez García EB; Hanson H; Izatt L; Kemp Z; Lalloo F; Lasset C; Lesueur F; Musgrave H; Nambot S; Noguès C; Oosterwijk JC; Stoppa-Lyonnet D; Tischkowitz M; Tripathi V; Wevers MR; Zhao E; van Leeuwen FE; Schmidt MK; Easton DF; Rookus MA; Antoniou AC
    J Med Genet; 2024 Jun; ():. PubMed ID: 38834293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective validation of the BOADICEA multifactorial breast cancer risk prediction model in a large prospective cohort study.
    Yang X; Eriksson M; Czene K; Lee A; Leslie G; Lush M; Wang J; Dennis J; Dorling L; Carvalho S; Mavaddat N; Simard J; Schmidt MK; Easton DF; Hall P; Antoniou AC
    J Med Genet; 2022 Dec; 59(12):1196-1205. PubMed ID: 36162852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and cost-effectiveness of four different strategies for SARS-CoV-2 surveillance in the general population (CoV-Surv Study): a structured summary of a study protocol for a cluster-randomised, two-factorial controlled trial.
    Deckert A; Anders S; de Allegri M; Nguyen HT; Souares A; McMahon S; Boerner K; Meurer M; Herbst K; Sand M; Koeppel L; Siems T; Brugnara L; Brenner S; Burk R; Lou D; Kirrmaier D; Duan Y; Ovchinnikova S; Marx M; Kräusslich HG; Knop M; Bärnighausen T; Denkinger C
    Trials; 2021 Jan; 22(1):39. PubMed ID: 33419461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer risk management among female BRCA1/2, PALB2, CHEK2, and ATM carriers.
    Cragun D; Weidner A; Tezak A; Clouse K; Pal T
    Breast Cancer Res Treat; 2020 Jul; 182(2):421-428. PubMed ID: 32445176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of evidence-based decision aids for women with pathogenic BRCA1 or BRCA2 variants in the german health care context: results from a randomized controlled trial.
    Kautz-Freimuth S; Redaèlli M; Shukri A; Kentenich H; Simic D; Mildenberger V; Schmutzler R; Rhiem K; Stock S
    BMC Med Inform Decis Mak; 2023 Oct; 23(1):223. PubMed ID: 37845719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Arthroscopic hip surgery compared with personalised hip therapy in people over 16 years old with femoroacetabular impingement syndrome: UK FASHIoN RCT.
    Griffin DR; Dickenson EJ; Achana F; Griffin J; Smith J; Wall PD; Realpe A; Parsons N; Hobson R; Fry J; Jepson M; Petrou S; Hutchinson C; Foster N; Donovan J
    Health Technol Assess; 2022 Feb; 26(16):1-236. PubMed ID: 35229713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
    Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
    Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feasibility and acceptability of personalised breast cancer screening (DECIDO study): protocol of a single-arm proof-of-concept trial.
    Pons-Rodriguez A; Forné Izquierdo C; Vilaplana-Mayoral J; Cruz-Esteve I; Sánchez-López I; Reñé-Reñé M; Cazorla C; Hernández-Andreu M; Galindo-Ortego G; Llorens Gabandé M; Laza-Vásquez C; Balaguer-Llaquet P; Martínez-Alonso M; Rué M;
    BMJ Open; 2020 Dec; 10(12):e044597. PubMed ID: 33361170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.
    Williams C; Brunskill S; Altman D; Briggs A; Campbell H; Clarke M; Glanville J; Gray A; Harris A; Johnston K; Lodge M
    Health Technol Assess; 2006 Sep; 10(34):iii-iv, ix-xi, 1-204. PubMed ID: 16959170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Women's responses and understanding of polygenic breast cancer risk information.
    Yanes T; Kaur R; Meiser B; Scheepers-Joynt M; McInerny S; Barlow-Stewart K; Antill Y; Salmon L; Smyth C; James PA; Young MA
    Fam Cancer; 2020 Oct; 19(4):297-306. PubMed ID: 32430685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population Study of Ovarian Cancer Risk Prediction for Targeted Screening and Prevention.
    Gaba F; Blyuss O; Liu X; Goyal S; Lahoti N; Chandrasekaran D; Kurzer M; Kalsi J; Sanderson S; Lanceley A; Ahmed M; Side L; Gentry-Maharaj A; Wallis Y; Wallace A; Waller J; Luccarini C; Yang X; Dennis J; Dunning A; Lee A; Antoniou AC; Legood R; Menon U; Jacobs I; Manchanda R
    Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32429029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extended genetic analysis and tumor characteristics in over 4600 women with suspected hereditary breast and ovarian cancer.
    Öfverholm A; Törngren T; Rosén A; Arver B; Einbeigi Z; Haraldsson K; Ståhlbom AK; Kuchinskaya E; Lindblom A; Melin B; Paulsson-Karlsson Y; Stenmark-Askmalm M; Tham E; von Wachenfeldt A; Kvist A; Borg Å; Ehrencrona H
    BMC Cancer; 2023 Aug; 23(1):738. PubMed ID: 37563628
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.